Senti Biosciences Inc (SNTI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.33-2.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SNTI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 322.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SNTI — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-09-02
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2026, the Company received (1) a written notice (the “Minimum Bid Price Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive trading days, the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum bid price requ…
Why it matters: Approval would bring in more funding. It would show that SENTI-202 works for AML.
Supportive ifSenti Bio files a Biologics License Application (BLA) for SENTI-202. It gets FDA approval.
Worry ifSenti Bio fails to file the BLA or receives a rejection from the FDA.
Why it matters: FDA approval would confirm the pathway for SENTI-202 in treating R/R AML. This could boost investor confidence and support future funding.
Supportive ifThe FDA approved the trial design for SENTI-202 in a public announcement.
Worry ifFDA denies or delays approval of the pivotal trial design for SENTI-202.
Why it matters: Finishing this would make operations easier. It would give more resources for SENTI-202.
Supportive ifThe merger with Celadon is complete. It is announced to shareholders.
Worry ifThe merger is delayed or canceled. This affects the plans for operations.
Why it matters: News on how Senti uses its money shows how it manages resources. This affects growth.
Worry ifA new plan about money use shows a good change in strategy.
Less concerning ifNo news or bad updates about money use in the next quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$297 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $928 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,608 loss on $10,000 · 86.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good capital use is important for Senti's growth and financial health.
Supportive ifManagement shares a clear plan for using capital.
Worry ifThere are no updates or unclear statements about capital use.
Why it matters: Good trial results would show SENTI-202's effectiveness. They would also show its market potential in AML.
Watch forSENTI-202 shows lasting MRD-negative responses in new trial results.
Also watch forTrial results show poor efficacy or safety concerns for SENTI-202.
Why it matters: Updates on cash will show if Senti Bio can pay for operations and trials.
Watch forCash and cash equivalents are above $6.5 million after the merger.
Also watch forCash and cash equivalents are below $6.5 million. This shows financial trouble.
Why it matters: Burning more cash may show financial problems and affect future work and growth.
Worry ifReported cash burn in Q2 exceeds $7.5 million.
Less concerning ifCash burn is below $7.5 million. This shows better financial management.
Why it matters: Updates on Celadon's stake may change Senti's control and future plans.
Watch forA press release confirming Celadon increases its stake beyond 54.6%.
Also watch forCeladon has not announced anything new about its stake in Senti.
Why it matters: The merger could unlock value for Senti's pipeline and provide funding for future projects.
Watch forCompletion of the merger and announcement of the contingent value rights tied to SENTI-202's success.
Also watch forIf the merger does not close or is delayed, it will hurt operations.
Why it matters: If revenue goes above this target, it shows better financial performance.
Supportive ifRevenue reported above $20,000 for Q2 2026.
Worry ifRevenue reported below $16,000 for Q2 2026.
Why it matters: Milestone payments could provide important funding. They would also show progress for SENTI-202.
Supportive ifSENTI-202 has achieved $200 million in total net sales.
Worry ifSales of SENTI-202 do not reach the $200 million target.
Why it matters: M&A activities may show growth chances for Senti Biosciences. Investors will look for signs of growth.
Supportive ifA press release will confirm a completed acquisition or partnership. This will expand Senti's market reach.
Worry ifNo announcements or progress on M&A activities over the next quarter.
Why it matters: Getting this funding is important for SENTI-202. It helps operations and shows financial health.
Supportive ifThey announced that they closed a $40 million financing deal.
Worry ifNot closing the financing agreement or delays in funding would be a problem.
Why it matters: If revenue growth in the health care sector speeds up, it may benefit Senti Biosciences.
Supportive ifHealth care sector revenue growth re-accelerates back toward its highs.
Worry ifSector revenue growth is slowing down. This shows there are still challenges ahead.
Why it matters: Finishing the spin-off will clarify Senti's focus. It may also help shareholders.
Supportive ifThe spin-off deal is complete. It has been announced to shareholders.
Worry ifThe spin-off transaction is delayed or canceled.
Why it matters: A bigger net loss shows worse financial health. It also means more operational problems.
Worry ifNet loss for Q2 exceeds $12.75 million.
Less concerning ifNet loss for Q2 is less than or equal to $12.75 million.
Why it matters: A lower cash position could mean money problems. This may affect operations.
Worry ifCash and cash equivalents are below $6.5 million.
Less concerning ifCash and cash equivalents are above $6.5 million.